Translating “Translation” – bridging the third translational gap
Lead Research Organisation:
Newcastle University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Organisations
- Newcastle University (Lead Research Organisation)
- CellCap Technologies (Collaboration)
- Novartis (Collaboration)
- Heptares Therapeutics Ltd (Collaboration)
- Mentis Cura (Collaboration)
- Eisai Ltd (Collaboration)
- Nascient ltd (Collaboration)
- AbbVie Inc (Collaboration)
- Eli Lilly & Company Ltd (Collaboration)
- Neuroelectrics (Collaboration)
- F. Hoffmann-La Roche AG (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Autifony Therapeutics (Collaboration)
- ElectroCore LLC (Collaboration)
People |
ORCID iD |
Publications
Grantham HJ
(2019)
The devil is in the data: differences in drug persistence between SNIIRAM, the French national health insurance database, and psoriasis biologics intervention registers.
in The British journal of dermatology
Hussain AB
(2019)
Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy.
in The British journal of dermatology
Pan S
(2020)
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.
in Clinical and translational science
Tsakok T
(2019)
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.
in JAMA dermatology
Watson N
(2019)
Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies.
in The British journal of dermatology
| Description | Case Studentship: Bioprinting Skin for Evaluation of Active Ingredients for the Cosmetic Industry |
| Amount | £52,000 (GBP) |
| Organisation | Croda Europe Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2021 |
| Description | Case Studentship: Electromagnetic spectrum on biomarkers of skin function and intervention of such effects" |
| Amount | £143,212 (GBP) |
| Organisation | Croda Europe Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2021 |
| Description | Genetech / Newcastle University collaboration (Lee Borthwick) |
| Amount | £58,500 (GBP) |
| Organisation | Genentech, Inc |
| Sector | Private |
| Country | United States |
| Start | 10/2017 |
| End | 12/2018 |
| Description | Newcastle / Takeda collaboration - Mark Cunningham |
| Amount | £598,312 (GBP) |
| Organisation | Takeda Pharmaceutical Company |
| Sector | Private |
| Country | Japan |
| Start | 01/2018 |
| End | 12/2021 |
| Description | Newcastle/Genentech collaboration |
| Amount | £0 (GBP) |
| Funding ID | Contract in final stages of negotiation contract amount is commercially sensitive information |
| Organisation | Genentech, Inc |
| Sector | Private |
| Country | United States |
| Start | 04/2017 |
| End | 03/2018 |
| Description | Personalised ultraviolet B (UVB) treatment of psoriasis through biomarker integration with computational modelling of psoriatic plaque resolution(2016 Interdisciplinary Prize Runner-Up - ST) |
| Amount | £250,000 (GBP) |
| Funding ID | M651 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 06/2020 |
| Description | MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop |
| Organisation | AbbVie Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop |
| Organisation | Eli Lilly & Company Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop |
| Organisation | F. Hoffmann-La Roche AG |
| Country | Global |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop |
| Organisation | Nascient ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge' |
| Organisation | Autifony Therapeutics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge' |
| Organisation | CellCap Technologies |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge' |
| Organisation | Eisai Ltd |
| Country | Japan |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge' |
| Organisation | ElectroCore LLC |
| Country | United States |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge' |
| Organisation | Heptares Therapeutics Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge' |
| Organisation | Mentis Cura |
| Country | Iceland |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge' |
| Organisation | Neuroelectrics |
| Country | Spain |
| Sector | Private |
| PI Contribution | Further details provided under Engagement Activities |
| Collaborator Contribution | Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions. |
| Impact | Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion. |
| Start Year | 2016 |
| Description | Chair plenary session Virtual Conference European Dermatology Forum |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Face to face meeting was cancelled due to COVID. A virtual meeting was held at which 4 plenary talks were presented from international high-level speakers. I co-chaired and introduced 2 speakers. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Diagnostic North East, Virtual Conference: closing remarks |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Promotion and description of Diagnostics North East to increase engagement and activity. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://diagnosticsnortheast.org.uk/ |
| Description | ESDR International Eczema Council: chair Human Models of Atopic Dermatitis symposium and introductory remarks; |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Introduction about the area and the IEC, brief presentations from each of the panel and then a round table discussion. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.eczemacouncil.org/index.php?option=com_jevents&task=icalrepeat.detail&evid=48&Itemid=115... |
| Description | Engaging with SMEs for drug repurposing in rare diseases |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | This is an activity in the planning phase only. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Eugene M Farber Lecture, SID, Chicago, USA |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | I presented the Eugene M Farber lecture entitled "Towards Precision Therapeutics: A Systems Approach to Understanding Psoriasis Plaque Resolution and Endotype Analysis" |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.2019sidannualmeeting.org/speakers/nick-reynolds-md/ |
| Description | MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dermatology activities included: Themed seminars including but not limited to systems biology approaches to psoriasis therapy, biomarkers of melanoma progression, topical treatment of non-melanoma skin cancer. Individual meetings with dermatological investigators covering psoriasis and biologics, atopic eczema, metastatic melanoma, phototherapy, connective diseases, open discussion of clinical unmet need and potential for novel therapeutic targets, open discussion of access to UK dermatological scientific and clinical community through UK TREND (http://www.uktrend.org/) and other networks. Rheumatology activities for the theme week included: Themed seminars including but not limited to inflammatory arthritis (including rheumatoid arthritis, spondyloarthropathy), osteoarthritis, Sjögren's syndrome, biomarkers and immune modulation. Individual meetings with rheumatology investigators covering early arthritis, resistant arthritis, Sjogren's syndrome, juvenile idiopathicarthritis, Spondyloarthropathy and connective tissue disease. In both cases activities included round-table discussion, one-to-one sessions, social gatherings and meetings with local patient groups. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.newcastleptd.com/ |
| Description | MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge' |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Themed seminars: short, problem focussed, used to highlight to attendees the current state of play in the field. Topics covered, but not limited to, will include: 'Designing clinical trials in Prodromal DLB'; 'Crash course in Lewy body pathology and opportunities for treatment'; 'What biomarkers do we have in early Lewy body dementia?'; Clinical demonstrations: histories from patient and carer volunteers to demonstrate clinical signs that typify LBD; representing areas of unmet therapeutic need and hence also market opportunities. Meeting patients and their carers: in order to allow 'real time' exploration of symptoms and problems that really matter to the person with LBD and their families, to highlight the clinical impact of these conditions. Demonstration of facilities: guided tours in small groups to demonstrate expertise and capability in areas such as human movement science, neurophysiology, image analysis, basic science laboratories and brain tissue resource / neuropathology. Individual meetings with Lewy body dementia investigators covering symptom targets, animal models, biomarker development, and clinical trial support will also be included. The audience (industry visitors) greatly appreciated the opportunity to discuss specific topics in small groups. Some have expressed a wish to collaborate further in future. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.newcastleptd.com/ |
| Description | Oncology workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oncology Workshop - showcasing our expertise in Oncology / Cancer research, and including NHS Observer Status to enable Industry representatives to attend NHS Clinics. Collaborations with industry were strengthened (new and existing relationships); 17 engaged external partners attended. Actively engaged in follow-on activities with partners. Poster / informal networking session gave attendees the opportunities to meet with ECRS, PG students, and the broader Newcastle Institute for Cancer Research community. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Regulatory requirements of medical and in vitro/ex vivo diagnostics devices |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | A half-day workshop delivered by an external medical device consultant and open to researchers from across FMS and SAgE with an interest in developing medical devices and understanding more about MHRA, CE marking and EU registration of medical devices. A more focussed 1.5 days of individual project development time between the consultant (Dr Keith Morris), researchers and Reece Innovation, based around specific devices already under development. As a consequence of this award Professor Baker and Dr Baker have been able to submit an MRC DPFS application for developing an electrodiagnostic device with Reece Innovation as a MICA partner. On the strength of the outline application, Dr Baker and Professor Baker have been invited to submit a full application. |
| Year(s) Of Engagement Activity | 2016 |